Increase of SialylatedN-Glycansin Eyes with Neovascular Glaucoma Secondary to Proliferative Diabetic Retinopathy

Abstract

Our data demonstrate the distinct changes of N-glycan profile and the increase of sialylated N-glycans in eyes with NVG secondary to PDR.

N-Glycan Profile and Kidney Disease in Type 1 Diabetes

“…However, previous studies of N-glycosylation in 562 people with type 2 diabetes reported reduced levels of certain monogalactosylated N-glycans (NG1 [6]A2F, equivalent to GP6 in our study) in people with type 2 diabetes compared with controls (18); this is consistent with the association of lower GP6 with higher HbA 1c found in our study. Another small study of 17 people with diabetes and controls found increased sialylated N-glycans in the vitreous fluid of people with proliferative retinopathy (19). A study of one specific glycoprotein, a1acid glycoprotein, in type 1 diabetes reported altered fucosylation (20).…”

Glycoblotting method allows for rapid and efficient glycome profiling of human Alzheimer's disease brain, serum and cerebrospinal fluid towards potential biomarker discovery

“…Internal standard (IS, A2amide, 110 pmole) was added according to the standard protocol [10][11][12][13][14][15][16][17][18][19][20][21][22][23][24]. The rest followed the same pretreatment as human brain tissue mentioned above.…”

“…By applying the general glycoblotting protocol for the human serum glycomics [13][14][15][16][17][18][19][20][21][22][23][24], we identified 52 N-glycans that can be used for further comparative study between AD patient and normal control group ( Table 2). The total expression levels of the serum N-glycans seemed to increase significantly in AD patients when compared with the normal control groups (p < 0.001 in male; p < 0.05 in female, Table 4).…”

“…We would like to express special appreciation to the Human Brain and Spinal Fluid Resource Center, (HBSFRC) and NINDS/NIMH, Los Angels, USA for giving a chance to analyze 24 invaluable human brain tissue, CSF, and Sera for this study. This work was partly supported by…”

“…To overcome the bottlenecks in the glycome analysis, we established the glycoblotting method, an easy, speedy, and highly efficient glycan enrichment process to perfectly purify and label glycans released from common glycoproteins and GSLs [10][11][12]. We have reported that dynamic alterations in the human serum glycoform profile are promising diagnostic biomarkers not only in cancers such as hepatocellular carcinoma [13][14][15], pancreatic cancer [16], renal cell carcinoma [17], and prostate cancer [18], but also in various diseases such as osteoarthritis [19,20], ulcerative colitis [21], nonalcoholic steatohepatitis [22], and diabetic retinopathy [23,24]. Recently, we have demonstrated the feasibility of this unique technology for analyzing and quantifying major glycans of Huntington's disease (HD) transgenic mice, in which the trend in the major glycoforms and expression levels of total glycans were different significantly between the HD transgenic and control group mice [25].…”